Inspire Medical Systems, Inc. (INSP)
USD 186.97
(-1.96%)
USD 186.97
(-1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 568.49 Million USD | 46.02% |
| 2022 | 389.33 Million USD | 62.25% |
| 2021 | 239.96 Million USD | 55.86% |
| 2020 | 153.96 Million USD | 49.04% |
| 2019 | 103.3 Million USD | 69.59% |
| 2018 | 60.91 Million USD | 58.01% |
| 2017 | 38.55 Million USD | 29.48% |
| 2016 | 29.77 Million USD | 19.1% |
| 2015 | 25 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 154.47 Million USD | -0.44% |
| 2024 Q2 | 160.94 Million USD | 4.19% |
| 2024 Q3 | 156.47 Million USD | -2.78% |
| 2023 FY | 568.49 Million USD | 46.02% |
| 2023 Q3 | 142.39 Million USD | -0.73% |
| 2023 Q2 | 143.43 Million USD | 12.5% |
| 2023 Q1 | 127.5 Million USD | 9.84% |
| 2023 Q4 | 155.15 Million USD | 8.97% |
| 2022 Q4 | 116.08 Million USD | 8.9% |
| 2022 Q2 | 91.22 Million USD | 20.93% |
| 2022 Q1 | 75.43 Million USD | 9.22% |
| 2022 FY | 389.33 Million USD | 62.25% |
| 2022 Q3 | 106.59 Million USD | 16.86% |
| 2021 Q3 | 62.85 Million USD | 8.4% |
| 2021 FY | 239.96 Million USD | 55.86% |
| 2021 Q1 | 50.06 Million USD | 9.04% |
| 2021 Q2 | 57.98 Million USD | 15.83% |
| 2021 Q4 | 69.06 Million USD | 9.87% |
| 2020 FY | 153.96 Million USD | 49.04% |
| 2020 Q1 | 34.49 Million USD | 7.92% |
| 2020 Q2 | 33.04 Million USD | -4.2% |
| 2020 Q3 | 40.52 Million USD | 22.64% |
| 2020 Q4 | 45.91 Million USD | 13.29% |
| 2019 Q3 | 26.05 Million USD | 12.73% |
| 2019 FY | 103.3 Million USD | 69.59% |
| 2019 Q1 | 22.17 Million USD | 21.41% |
| 2019 Q4 | 31.96 Million USD | 22.65% |
| 2019 Q2 | 23.11 Million USD | 4.24% |
| 2018 Q1 | 12.94 Million USD | 8.56% |
| 2018 Q2 | 14.47 Million USD | 11.82% |
| 2018 Q3 | 15.23 Million USD | 5.27% |
| 2018 Q4 | 18.26 Million USD | 19.87% |
| 2018 FY | 60.91 Million USD | 58.01% |
| 2017 Q1 | 8.22 Million USD | 0.0% |
| 2017 FY | 38.55 Million USD | 29.48% |
| 2017 Q2 | 9.05 Million USD | 10.03% |
| 2017 Q3 | 9.35 Million USD | 3.37% |
| 2017 Q4 | 11.92 Million USD | 27.44% |
| 2016 FY | 29.77 Million USD | 19.1% |
| 2015 FY | 25 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 96.382% |
| Allurion Technologies Inc. | 120.57 Million USD | -371.486% |
| Artivion, Inc. | 223.43 Million USD | -154.435% |
| Avanos Medical, Inc. | 375.5 Million USD | -51.397% |
| Butterfly Network, Inc. | 162.46 Million USD | -249.916% |
| Butterfly Network, Inc. | 162.46 Million USD | -249.916% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 45.731% |
| Boston Scientific Corporation | 7.47 Billion USD | 92.398% |
| Perspective Therapeutics, Inc. | 17.42 Million USD | -3162.332% |
| CONMED Corporation | 564.24 Million USD | -0.754% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 81.607% |
| Paragon 28, Inc. | 210.1 Million USD | -170.583% |
| Glaukos Corporation | 367.83 Million USD | -54.551% |
| Globus Medical, Inc. | 887.16 Million USD | 35.92% |
| Integer Holdings Corporation | 250.95 Million USD | -126.529% |
| Medtronic plc | 16.12 Billion USD | 96.475% |
| Nevro Corp. | 389.36 Million USD | -46.004% |
| Owlet, Inc. | 51.21 Million USD | -1009.928% |
| Penumbra, Inc. | 590.87 Million USD | 3.788% |
| Vicarious Surgical Inc. | 80.66 Million USD | -604.75% |
| Smith & Nephew plc | 3.46 Billion USD | 83.603% |
| Sonendo, Inc. | 68.46 Million USD | -730.343% |
| STERIS plc | 1.4 Billion USD | 59.404% |
| Stryker Corporation | 9.2 Billion USD | 93.827% |
| Vapotherm, Inc. | 66.02 Million USD | -761.028% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 82.647% |